# US 2025/0375405 A1 · N-lactoyl-phenylalanine for preventing and/or treating ischemic heart disease and method for preventing and/or treating ischemic heart disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375405 A1
- Document ID: US20250375405A1
- Status: Published application
- Kind: A1
- Application number: 18/940,875
- Filed: 2024-11-08
- Published: 2025-12-11
- Earliest claimed: 2024-06-07
- Assignees: Harbin Medical University
- Applicants: Harbin Medical University
- Inventors: Yang ZHANG; Lei JIAO; Zheng LI; Zhiyuan DU; Manyu GONG; Yu WANG; Chenchen YIN; Tiantian GONG
- Web page: https://patentgrep.com/patent/US20250375405A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A use of N-lactoyl-phenylalanine (Lac-Phe) in a preparation of a medicament for preventing and/or treating ischemic heart disease is provided. It is the first to demonstrate that Lac-Phe can improve the cardiac function in a mouse model of left anterior descending coronary artery stenosis, promote cardiac angiogenesis, improve the viability of hypoxic cardiomyocytes, and inhibit the expression of inflammatory cytokines in the heart, thereby playing an anti-myocardial ischemic injury role. Therefore, the Lac-Phe can be used to prepare a medicament for treating ischemic heart disease. A novel technical means for the treatment of ischemic heart disease is provided.

## Claims

### Claim 1

A method for preventing and/or treating an ischemic heart disease, comprising: administering to a subject a medicament comprising N-lactoyl-phenylalanine (Lac-Phe) or a pharmaceutically acceptable salt thereof in an effective amount,
wherein a structure of the Lac-Phe is as follows:

### Claim 2 (depends on 1)

The method according to claim 1, wherein the ischemic heart disease is selected from the group consisting of coronary heart disease, myocardial infarction, myocardial ischemia-reperfusion injury, myocardial hypertrophy, arrhythmia, and heart failure caused by myocardial ischemia.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the ischemic heart disease is an ischemic heart disease in an obese patient.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the Lac-Phe or the pharmaceutically acceptable salt thereof has an effect of alleviating cardiac dysfunction, heart inflammation, and cardiomyocyte death caused by myocardial ischemia.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the medicament further comprises a pharmaceutically acceptable carrier or excipient.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the medicament is an oral preparation, a sublingual preparation, or an injection preparation.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the medicament is an oral preparation, a sublingual preparation, or an injection preparation.

### Claim 8 (depends on 3)

The method according to claim 3, wherein the medicament is an oral preparation, a sublingual preparation, or an injection preparation.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the medicament is an oral preparation, a sublingual preparation, or an injection preparation.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the medicament is an oral preparation, a sublingual preparation, or an injection preparation.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the oral preparation, the sublingual preparation, or the injection preparation is one selected from the group consisting of a tablet, a capsule, a granule, an oral solution, and an injection.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the oral preparation, the sublingual preparation, or the injection preparation is one selected from the group consisting of a tablet, a capsule, a granule, an oral solution, and an injection.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the oral preparation, the sublingual preparation, or the injection preparation is one selected from the group consisting of a tablet, a capsule, a granule, an oral solution, and an injection.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the oral preparation, the sublingual preparation, or the injection preparation is one selected from the group consisting of a tablet, a capsule, a granule, an oral solution, and an injection.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the oral preparation, the sublingual preparation, or the injection preparation is one selected from the group consisting of a tablet, a capsule, a granule, an oral solution, and an injection.
